United States biological products, excluding disgnostic substances industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Biological Products, Excluding Disgnostic Substances Stocks in USA: Prism Readiness Cohort 7

Name: Biological Products, Excluding Disgnostic Substances Stocks in USA: Prism Readiness Cohort 7 comparison snapshot
Creator: Fliar BI Prism

A five-company biological products, excluding disgnostic substances cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness

Readiness leaderAtara Biotherapeutics · 43

Strongest available pathMeiraGTx · +7.7%

Widest latest marginAtara Biotherapeutics · 27.1%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1ATRA · Nasdaq

Atara Biotherapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2021San Francisco, California$90.5M market cap

View full Companies Radar profile

43Cautious

Snapshot price$9.02as of page date

Monthly-close return-98.0%five-year window

FY2025 revenue$0.12BAtara Biotherapeutics, Inc.

Net margin27.1%FY2025

P/E snapshot5.8xone ratio, not a verdict

Prism attention13.7%share across these five

Filing track recordRevenue, USD billions

+1308.7%

FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 275.3%

52-week position34% through range

$3.92$19.14

News mentions1.4K

Community mentions22partial coverage

U.S.-scope patents84

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal40/100
Management stability90/100
Market position9/100
Capital-event signal74/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 5 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 9 asset-acquisition events and 9 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2EDIT · Nasdaq

Editas Medicine

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2013Cambridge, Massachusetts$471.5M market cap

View full Companies Radar profile

43Cautious

Snapshot price$3.07as of page date

Monthly-close return-92.5%five-year window

FY2025 revenue$0.04BEditas Medicine, Inc.

Net margin-395.0%FY2025

P/E snapshot-4.1xone ratio, not a verdict

Prism attention15.9%share across these five

Filing track recordRevenue, USD billions

+58.6%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 12.2%

52-week position49% through range

$1.66$4.54

News mentions1.7K

Community mentions142partial coverage

U.S.-scope patents714

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal50/100
Management stability90/100
Market position0/100
Capital-event signal65/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3DNA · NYSE

Ginkgo Bioworks

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2011Boston, Massachusetts$466.7M market cap

View full Companies Radar profile

42Cautious

Snapshot price$6.93as of page date

Monthly-close return-98.5%five-year window

FY2025 revenue$0.17BGinkgo Bioworks Holdings, Inc.

Net margin-183.8%FY2025

P/E snapshot-2.4xone ratio, not a verdict

Prism attention53.5%share across these five

Filing track recordRevenue, USD billions

-45.8%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -14.2%

52-week position13% through range

$5.37$17.58

News mentions5.6K

Community mentions193partial coverage

U.S.-scope patents385

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal26/100
Management stability90/100
Market position25/100
Capital-event signal75/100
Innovation pulse3/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 34 M&A involvements, 5 asset-acquisition events and 8 contract events.

Innovation activity

Prism records 3 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4MGTX · Nasdaq

MeiraGTx

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2015New York City, New York$1.36B market cap

View full Companies Radar profile

42Cautious

Snapshot price$14.19as of page date

Monthly-close return+7.7%five-year window

FY2021 revenue$0.02BMeiraGTx Holdings plc

Net margin-814.2%FY2021

P/E snapshot16.3xone ratio, not a verdict

Prism attention5.0%share across these five

Filing track recordRevenue, USD billions

+19.8%

FY2019–FY2021 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 9.4%

52-week position87% through range

$6.62$15.35

News mentions522

Community mentions0partial coverage

U.S.-scope patents24

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal61/100
Management stability90/100
Market position11/100
Capital-event signal31/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 5 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5VIVS · Nasdaq

Organovo

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2007San Diego$3.7M market cap

View full Companies Radar profile

41Cautious

Snapshot price$0.28as of page date

Monthly-close return-99.7%five-year window

FY2025 revenue$0.00BVivoSim Labs, INC.

Net margin-1727.8%FY2025

Prism attention11.9%share across these five

Filing track recordRevenue, USD billions

-93.4%

FY2020–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -49.4%

52-week position0% through range

$0.26$5.30

News mentions1.2K

Community mentions0partial coverage

U.S.-scope patents273

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal32/100
Management stability90/100
Market position17/100
Capital-event signal65/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 9 M&A involvements, 3 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

MeiraGTx

+7.7%

Editas Medicine

-92.5%

Atara Biotherapeutics

-98.0%

Ginkgo Bioworks

-98.5%

Organovo

-99.7%

Latest revenue

USD billions, official filing scope shown on each company card.

Ginkgo Bioworks

$0.17B

Atara Biotherapeutics

$0.12B

Editas Medicine

$0.04B

MeiraGTx

$0.02B

Organovo

$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Atara Biotherapeutics

27.1%

Ginkgo Bioworks

-183.8%

Editas Medicine

-395.0%

MeiraGTx

-814.2%

Organovo

-1727.8%

Prism news attention

Normalized share across these five names; attention is not quality.

Ginkgo Bioworks

53.5%

Editas Medicine

15.9%

Atara Biotherapeutics

13.7%

Organovo

11.9%

MeiraGTx

5.0%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized biological products, excluding disgnostic substances news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Ginkgo Bioworks leads the conversation

It holds 53.5% of measured biological products, excluding disgnostic substances news attention and also carries the basket's largest revenue base at $0.17B.

Price path

MeiraGTx leads the available price paths

Its monthly-close return is +7.7% for the five-year window. At the other end, Organovo is -99.7% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Atara Biotherapeutics has the widest latest margin

Its FY2025 net margin is 27.1%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Editas Medicine shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -4.1x while its five-year window price return is -92.5%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · ATRA

Atara Biotherapeutics

1,429available Prism news records

Prism top themes

Leadership & governance

Price action & investor response

Legal, arbitration & regulatory

Capital allocation & transactions

Earnings & financial performance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+4.7%199 latest 12m vs 190 prior 12m

Machine-classified coverage tone

80.4% positive-14.1 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

cell-based therapies 25gene therapy rare diseases 21stock performance 14relapsed hodgkin's immunotherapy 9cell therapy 9immunotherapy 9rare disease treatment 8stem cell banking 7

Keyword tag occurrences in available Prism news records.

Coverage: 2012-10-26–2026-05-26 · trend and themes shown through 2026-05

Areas of research · EDIT

Editas Medicine

1,665available Prism news records

Prism top themes

Price action & investor response

Legal, arbitration & regulatory

Leadership & governance

Capital allocation & transactions

Earnings & financial performance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-15.9%164 latest 12m vs 195 prior 12m

Machine-classified coverage tone

90.2% positive-2.9 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

crispr-cas9 68crispr applications 68gene therapy rare diseases 68cell-based therapies 27stem cell banking 27gene knockout 24gene delivery systems 20gene therapy studies 18

Keyword tag occurrences in available Prism news records.

Coverage: 2013-11-25–2026-06-03 · trend and themes shown through 2026-06

Areas of research · DNA

Ginkgo Bioworks

5,592available Prism news records

Prism top themes

Price action & investor response

Leadership & governance

Earnings & financial performance

Capital allocation & transactions

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-9.6%637 latest 12m vs 705 prior 12m

Machine-classified coverage tone

81.4% positive-6.6 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

synthetic biology 81enzyme engineering 60reforestation 56native species preservation 55forest conservation 55conservation status 54biodiversity monitoring 54extinction prevention 54

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-19 · trend and themes shown through 2026-06

Areas of research · VIVS

Organovo

1,241available Prism news records

Prism top themes

Leadership & governance

Price action & investor response

Capital allocation & transactions

Macro demand & rates

Earnings & financial performance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-22.2%77 latest 12m vs 99 prior 12m

Machine-classified coverage tone

95.9% positive+3.1 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

3d printer software 21additive manufacturing system 17wearable biotech 11biomaterials 113d printed drugs 83d printed implants 8anti-tnf therapy crohn's 7biologic agents crohn's 7

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-02–2026-06-01 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

EDIT

Editas Medicine

142 mentions

Stock and valuation

Products, pricing and logistics

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 142 records remained after filtering.

DNA

Ginkgo Bioworks

193 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 193 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

ATRA

Atara Biotherapeutics

through 2026-03-25

Earnings releases 7Leadership changes 6Company announcements 2Asset acquisitions 1Lawsuits 1

2026-03-25
Lawsuits
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Atara Biotherapeutics, Inc. securities between May 20, 2024 and January 9, 2026.
2025-09-04
Leadership changes
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Greg Ciongoli will assume the role of Chair of the Board of Directors.
2025-05-15
Earnings releases
Total revenues were $98.1 million for the first quarter 2025, as compared to $27.4 million for the same period in 2024.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

EDIT

Editas Medicine

through 2026-01-01

Earnings releases 9Leadership changes 8Listing / IPO 2

2026-01-01
Leadership changes
Editas Medicine, Inc., a genome editing company, has appointed Bernadette Connaughton to its board of directors.
2025-04-01
Earnings releases
Zacks Research also issued estimates for Editas Medicine’s FY2025 earnings at ($2.62) EPS.
2025-02-14
Listing / IPO
Editas Medicine Inc. filed an S-1 with the SEC seeking to raise up to $100 million, including overallotments, in an IPO.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

DNA

Ginkgo Bioworks

through 2026-02-19

Earnings releases 24Company announcements 4Business contracts 3Asset acquisitions 2Lawsuits 2

2026-02-19
Company announcements
Ginkgo Bioworks Holdings, Inc. today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, beginning at 4:30 p.m. ET.
2025-11-17
Leadership changes
He’ll take over for Patrick DePriest, who took off for Texas-based manufacturer Saronic Technologies about 10 months ago.
2025-11-07
Earnings releases
Ginkgo Bioworks reported a loss of $1.45 per share versus estimates for a loss of $1.24 per share and a loss of $1.08 per share in the same period last year, representing a 34.26% increase in losses year over year.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

MGTX

MeiraGTx

through 2025-08-15

Asset acquisitions 5Earnings releases 5Regulatory 2Business contracts 1M&A 1

2025-08-15
Earnings releases
Meiragtx Holdings ( (MGTX) ) has released its Q2 earnings.
2025-06-26
Regulatory
MeiraGTx Holdings plc has received the necessary clearances and approvals under the UK’s foreign direct investment laws for its proposed transactions with Hologen Limited, which were initiated on March 9, 2025.
2025-03-14
Business contracts
Hologen has committed up to $430m in funding to support the development and commercialisation of AAV-GAD, MeiraGTx’s investigational gene therapy for Parkinson’s disease. The AI company will provide $200m upfront and allocate up to $230m in additional capital to fully finance the programme.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

VIVS

Organovo

through 2025-04-03

Leadership changes 4Asset acquisitions 3Company announcements 1Earnings releases 1Lawsuits 1

2025-04-03
Earnings releases
Organovo’s preliminary cash and cash equivalents balance was approximately $11.3 million as of the end of the fiscal year on March 31, 2025.
2025-03-26
Asset acquisitions
Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced the successful close of the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company (NYSE:LLY) (“Lilly”). The transaction was completed on March 25, 2025.
2025-03-20
Company announcements
Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced that it will effect a 1-for-12 reverse stock split of its issued and outstanding common stock that will become effective at 5:00 p.m. Eastern Time on Thursday, March 20, 2025.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Biological Products, Excluding Disgnostic Substances Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary biological products, excluding disgnostic substances news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

biologics market

26 sources67.0% extraction confidence

2020 extracted base$194.20B–$477.15B

2033 extracted forecast$685.30B–$1.37T

Implied source CAGR8.5%

high demand for the treatment of different disease indicationsTechnologyadvancements in biotechnology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, North America, Mexico. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Biological Products, Excluding Disgnostic Substances news pulse

24,998available Prism news records

Latest 12m volume+9.8%10786 vs 9825 records

Positive classified tone41.7%+4.6 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching biological, disgnostic, excluding, substance, biologic. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

harm reduction strategies

4,078

substance abuse education

3,736

opioid addiction and treatment

3,643

overdose prevention techniques

3,482

controlled substance regulations

3,381

substance abuse overdose fatalities

3,287

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

mind-altering drug consumption 1,795opioid diversion abuse 1,702fentanyl treatment programs 1,649drug overdose 1,576cannabis policy reform discussions 1,328psychedelic mental health studies 1,328medication-assisted treatment opioids 1,265psychoactive drug intake 1,170

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

high demand for the treatment of different disease indications

26 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

harm reduction strategies

4,078 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

2,049 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

Biosimilars entering the market

1,542 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+9.8% news volume

The latest 12 months contain 10,786 matched records versus 9,825 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

41.7% positive · +4.6pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2836 (Biological Products, Excluding Disgnostic Substances), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 31–38. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Biological Products, Excluding Disgnostic Substances Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Atara Biotherapeutics leads the readiness ranking

Its Prism readiness score is 43/100, the highest in this five-company comparison.

Open Atara Biotherapeutics in Companies Radar

Scale and margin leadership sit with Ginkgo Bioworks and Atara Biotherapeutics

Ginkgo Bioworks has the largest displayed latest revenue at $0.17B; Atara Biotherapeutics has the widest displayed latest margin at 27.1%.

Open Ginkgo Bioworks in Companies Radar Open Atara Biotherapeutics in Companies Radar

Comparisons

Strongest versus weakest available price path

MeiraGTx is +7.7% for its five-year window; Organovo is -99.7% for its five-year window.

Open MeiraGTx in Companies Radar Open Organovo in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.17B for Ginkgo Bioworks to $0.00B for Organovo. Entity and filing-period labels remain visible on the company cards.

Open Ginkgo Bioworks in Companies Radar Open Organovo in Companies Radar

Anomalies

Ginkgo Bioworks has the widest attention-readiness rank gap

It ranks #1 by measured news attention (53.5%) and #3 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Ginkgo Bioworks in Companies Radar

Atara Biotherapeutics shows a price-operating divergence to inspect

Its displayed filing-revenue change is +1308.7% while its available monthly-close return is -98.0%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Atara Biotherapeutics in Companies Radar

Explanations

Attention measures coverage volume, not quality

Ginkgo Bioworks's 53.5% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Ginkgo Bioworks in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Atara Biotherapeutics's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 43/100 score.

Open Atara Biotherapeutics in Companies Radar

Stress-test the largest divergence before forming a view

Compare Atara Biotherapeutics's profile with MeiraGTx's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Atara Biotherapeutics in Companies Radar Open MeiraGTx in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.